Starpharma announced it has signed a new DEP research agreement with MSD, the trade name of Merck Sharp & Dohme LLC, Rahway, New Jersey, USA. This new agreement follows an earlier DEP antibody drug conjugate (ADC) agreement signed with MSD in February 2021.
Under the new agreement, Starpharma will design and synthesize a number of DEP dendrimer conjugates and will provide them to MSD for testing and characterisation.
Dr Jackie Fairley, CEO of Starpharma commented:
